NGENFNervGen PharmaNGENF info
$2.16info27.06%24h
Global rank18840
Market cap$128.53M
Change 7d10.20%
YTD Performance5.88%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    NervGen Pharma (NGENF) Stock Overview

    NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

    NGENF Stock Information

    Symbol
    NGENF
    Address
    2955 Virtual WayVancouver, BC V5M 4X6Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.nervgen.com
    Country
    🇨🇦 Canada
    Phone Number
    778-731-1711

    NervGen Pharma (NGENF) Price Chart

    -
    Value:-

    NervGen Pharma Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.16
    N/A
    Market Cap
    $128.53M
    N/A
    Shares Outstanding
    59.51M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org